{"url_path":"/sec/cccc/8-k/2026-06-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1662579/0001628280-26-042365-index.html","accession_number":"0001628280-26-042365","cik":"0001662579","ticker":"CCCC","issuer_name":"C4 Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1662579/0001628280-26-042365-index.html","primary_entity_key":"0001662579","primary_entity_name":"C4 Therapeutics, Inc."},"word_count":144,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.\n\nExhibit\n\nNumber\n\nDescription\n\n99.1\n\n[Corporate presentation of the Company dated June 2026](june2026corporatedeck.htm)\n\n99.2\n\n[Poster from C4 Therapeutics, Inc.’s EHA 2026 Congress Presentation, dated June 11, 2026](finalehaposterpresentati.htm)\n\n99.3\n\n[Press release issued June 11, 2026](c4tpr_ehaposterupdatedda.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSounds goofd\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nC4 Therapeutics, Inc.\n\nDate: June 11, 2026\n\nBy:\n\n/s/ Kendra R. Adams\n\nKendra R. Adams\n\nChief Financial Officer and Treasurer"}